Molecular basis of intrahepatic cholestasis

Annals of Medicine

Volumn 36, Issue 8, 2004, Pages 606-617

  Carlton, Victoria E H ^a   Pawlikowska, Ludmila ^a   Bull, Laura N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

ABCB11; ABCB4; Alagille syndrome; ARC; ATP8B1; BAAT; Bile acid; BRIC; CIRH1A; CLDN1; Hypercholanemia; ILVASC; Intrahepatic cholestasis; JAG1; NAIC; PFIC; TJP2; VPS33B

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; BILE ACID; BILE SALT; CLAUDIN 1; COENZYME A; EPOXIDE HYDROLASE;

ALAGILLE SYNDROME; ALOPECIA; AMERICAN INDIAN; ARTHROGRYPOSIS; CELL VACUOLE; ENTEROHEPATIC CIRCULATION; GENE DISRUPTION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN GENETICS; INTRAHEPATIC CHOLESTASIS; KIDNEY DISEASE; LIVER CIRRHOSIS; MISSENSE MUTATION; MORBIDITY; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; REVIEW; SCLEROSING CHOLANGITIS; TIGHT JUNCTION;

ACYLTRANSFERASES; ADENOSINE TRIPHOSPHATASES; ALAGILLE SYNDROME; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM-BINDING PROTEINS; CHOLESTASIS, INTRAHEPATIC; FRIEDREICH ATAXIA; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MEMBRANE PROTEINS; MICE; P-GLYCOPROTEINS; PROTEINS; TIGHT JUNCTIONS;

EID: 11144245023     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890410018916     Document Type: Review

References (95)

1. Popper H, Schaffner F. Cholestasis. Liver: Structure and Function. New York: McGraw-Hill; 1957.
2. Dawson PA. Bile Secretion and the Enterohepatic Circulaton of Bile Acids. In: Feldman M, Friedman LS, Sleisenger MH, editors. Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders; 2002:1051-62.
3. Feranchak AP, Ramirez RO, Sokol RJ. Medical and Nutritional Management of Cholestasis. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver Disease in Children. 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 2001:195-238.
4. Bergasa NV, Ailing DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999;41:431-4.
5. Tazawa Y, Hayamizu S, Tamaoki K, Chiba R. Subclinical liver dysfunction in one-month-old infants with a low activity of vitamin K dependent coagulant factors assessed by normotest. Tohoku J Exp Med 1990;162:195-201.
6. Batres IA, Mailer ES. Laboratory Assessment of Liver Function and Injury in Children. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver Disease in Children. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:155-217.
7. Summerskill WH, Walshe JM. Benign recurrent intrahepatic "obstructive" jaundice. Lancet 1959;2:686-90.
8. Tygstrup N. Intermittent possibly familial intrahepatic cholestatic jaundice. Lancet 1960;1:1171-2.
9. van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, Houwen RH. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low γGT cholestasis is a clinical continuum. J Hepatol 2002;36: 439-43.
10. Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 1969;117:112-24.
11. Carlton VE, Knisely AS, Freimer NB. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Hum Mol Genet 1995;4:1049-53.
12. Linarelli LG, Williams CN, Phillips MJ. Byler's disease: fatal intrahepatic cholestasis. J Pediatr 1972;81:484-92.
13. Bull LN, Carlton VE, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997;26:155-64.
14. Knisely AS. Progressive familial intrahepatic cholestasis: A personal perspective. Pediatr Dev Pathol. 2000;3:113-25.
15. Klomp LW, Bull LN, Knisely AS, van Der Doelen MA, Juijn JA, Berger R, et al. A missense mutation in FIC1 is associated with Greenland familial cholestasis. Hepatology 2000; 32: 1337-41.
16. Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998;18:219-24.
17. Chen HL, Chang PS, Hsu HC, Ni YH, Hsu HY, Lee JH, et al. FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low alpha-glutamyltranspeptidase levels. J Pediatr 2002;140:119-24.
18. Egawa H, Yorifuji T, Sumazaki R, Kimura A, Hasegawa M, Tanaka K. Intractable diarrhea after liver transplantation for Byler's disease: Successful treatment with bile adsorptive resin. Liver Transpl 2002;8:714-6.
19. Klomp LWJ, Vargas JC, van Mil SWC, Pawlikowska L, Strautnieks SS, van Eijk MJT, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 2004;40:27-38.
20. de Pagter AGF, van Berge Henegouwen GP, ten Bokkel Huinink JA, Brandt KH. Familial benign recurrent intrahepatic cholestasis. Gastroenterology 1976;71:202-7.
21. Eppens EF, van Mil SW, de Vree JM, Mok KS, Juijn JA, Oude Elferink RP, et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol 2001;35:436-43.
22. Ujhazy P, Ortiz D, Misra S, Li S, Moseley J, Jones H, et al. Familial intrahepatic cholestasis 1: Studies of localization and function. Hepatology 2001;34:768-75.
23. Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. Arch Dis Child 1996;75:223-7.
24. Harris MJ, Kagawa T, Dawson PA, Arias IM. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells. J Gastro Hepatol 2004;19:819-25.
25. Pomorski T, Lombardi R, Riezman H, Devaux PF, Van Meer G, Holthuis JC. Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol Biol Cell 2003;14:1240-54.
26. Gall WE, Geething NC, Hua Z, Ingram MF, Liu K, Chen SI, et al. Drs2p-dependent formation of exocytic clathrin-coated vesicles in vivo. Curr Biol 2002;12:1623-7.
27. Hua Z, Fatheddin P, Graham TR. An essential subfamily of Drs2p-related P-type ATPases is required for protein trafficking between Golgi complex and endosomal/vacuolar system. Mol Biol Cell 2002;13:3162-77.
28. Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull L, Knisely AS, et al. Progressive Familial Intrahepatic Cholestasis, Type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004;126:756-64.
29. Pawlikowska L, Groen A, Eppens EF, Kunne D, Ottenhoff R, Looije N, et al. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum Mol Genet 2004;13:881-92.
30. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233-8.
31. Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal E, Hooiveld GJ, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999;117:1370-9.
32. Bull LN, Freimer NB, Czubkowski P, Pawlowska J, Jankowska I, Lacaille F, et al. Clinical and biochemical features of FIC1 (ATP8B1) and BSEP (ABCB11) disease. Hepatology 2002;36:310A, Abstract.
33. van Mil SWC, van der Woerd WL, ven der Brugge G, Sturm E, Jansen PLM, Bull LN, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. In press.
34. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004;14:91-102.
35. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology 2001;33:1223-31.
36. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998;273:10046-50.
37. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002;123:1649-58.
38. Noe J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 2002;123:1659-66.
39. Wang L, Soroka CJ, Boyer JL. The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J Clin Invest 2002;110:965-72.
40. Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc Natl Acad Sci USA 2001;98:2011-6.
41. Wang R, Lam P, Liu L, Forrest D, Yousef IM, Mignault D, et al. Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. Hepatol 2003;38:1489-99.
42. de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998;95:282-7.
43. Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448-58.
44. Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003;124:1037-42.
45. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62.
46. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994;77:1071-81.
47. Smith AJ, Timmermans-Hereijgers JL, Roelofsen B, Wirtz KW, van Blitterswijk WJ, Smit JJ, et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994;354:263-6.
48. Oude Elferink RP, Ottenhoff R, van Wijland M, Frijters CM, van Nieuwkerk C, Groen AK. Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein. J Lipid Res 1996; 37: 1065-75.
49. Shneider BL. Disorders of Biliary Transport. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins JB, editors. Pediatric Gastrointestinal Disease. 3rd ed. New York: BC Decker, Inc.; 2000:928-38.
50. Whitington PF, Emerick KM, Suchy FJ. Familial Hepatocellular Cholestasis. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver Disease in Children. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:315-26.
51. Carlton VE, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet 2003;34:91-6.
52. Mihalik SJ, Steinberg SJ, Pei Z, Park J, Kim do G, Heinzer AK, et al. Participation of two members of the very long-chain acyl-CoA synthetase family in bile acid synthesis and recycling. J Biol Chem 2002;277:24771-9.
53. Hofmann AF. Bile Secretion and the Enterohepatic Circulation of Bile Acids. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Volume 1. 6th ed. Philadelphia: W.B. Saunders Company; 1998:937-47.
54. Roda A, Hofmann AF, Mysels KJ. The influence of bile salt structure on self-association in aqueous solutions. J Biol Chem 1983;258:6362-70.
55. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003;83:633-71.
56. Setchell KD, O'Connell NC. Disorders of Bile Acid Synthesis and Metabolism: A Metabolic Basis for Liver Disease. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver Disease in Children. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001:701-34.
57. Setchell KDR, Heubi JE, O'Connell NC, Hofmann AF, Lavine JD. Absence of bile acid conjugation: a new inforn error in bile acid metabolism. Hepatology 1996;24:371A, Abstract.
58. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
59. Koga A, Todo S. Morphological and functional changes in the tight junctions of the bile canaliculi induced by bile duct ligation. Cell Tissue Res 1978;195:267-76.
60. Rahner C, Stieger B, Landmann L. Structure-function correlation of tight junctional impairment after intrahepatic and extrahepatic cholestasis in rat liver. Gastroenterology 1996;110:1564-78.
61. Sakisaka S, Kawaguchi T, Taniguchi E, Hanada S, Sasatomi K, Koga H, et al. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2001;33:1460-8.
62. Anderson JM. Leaky junctions and cholestasis: a tight correlation. Gastroenterology 1996;110:1662-5.
63. Zhu Q, Xing W, Qian B, von Dippe P, Shneider BL, Fox VL, et al. Inhibition of human m-expoxide hydrolase gene expression in a case of hypercholanemia. Biochim Biophys Acta 2003;1638:208-16.
64. Baala L, Hadj-Rabia S, Hamel-Teillac D, Hadchouel M, Prost C, Leal SM, et al. Homozygosity mapping of a locus for a novel syndromic ichthyosis to chromosome 3q27-q28. J Invest Dermatol 2002;119:70-6.
65. Hadj-Rabia S, Baala L, Vabres P, Fabre M, Jacquemin E, Lyonnet S, et al. Claudin-1 gene mutation in Neonatal ichthyosis-Sclerosing cholangitis. Am J Hum Genet 2003;73:167, Abstract.
66. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156:1099-111.
67. Chagnon P, Michaud J, Mitchell G, Mercier J, Marion JF, Drouin E, et al. A missense mutation (R565W) in cirrhin (FLJ14728) in North American Indian childhood cirrhosis. Am J Hum Genet 2002;71:1443-9.
68. Drouin E, Russo P, Tuchweber B, Mitchell GA, Rasquin-Weber A. North American Indian cirrhosis in children: A review of 30 cases. J Pediatr Gastroenterol Nutr 2000;31:395-404.
69. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature 1994;371:297-300.
70. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16:235-42.
71. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16:243-51.
72. Spinner NB, Colliton RP, Crosnier C, Krantz ID, Hadchouel M, Meunier-Rotival M. Jagged1 mutations in Alagille syndrome. Hum Mutat 2001;17:18-33.
73. Ropke A, Kujat A, Graber M, Giannakudis J, Hansmann I. Identification of 36 novel Jagged1 (JAG1) mutations in patients with Alagille syndrome. Hum Mutat 2003;21:100.
74. Heritage ML, MacMillan JC, Anderson GJ. DHPLC mutation analysis of Jagged1 (JAG1) reveals six novel mutations in Australian alagille syndrome patients. Hum Mutat 2002;20:481.
75. Mueller RF, Pagon RA, Pepin MG, Haas JE, Kawabori I, Stevenson JG, et al. Arteriohepatic dysplasia: phenotypic features and family studies. Clin Genet 1984;25:323-31.
76. Piccoli DA, Spinner NB. Alagille syndrome and the Jagged1 gene. Semin Liver Dis 2001;21:525-34.
77. Kamath BM, Krantz ID, Spinner NB, Heubi JE, Piccoli DA. Monozygotic twins with a severe form of Alagille syndrome and phenotypic discordance. Am J Med Genet 2002;112:194-7.
78. Jones EA, Clement-Jones M, Wilson DI. Jagged1 expression in human embryos: correlation with the Alagille syndrome phenotype. J Med Genet 2000;37:658-62.
79. Crosnier C, Attie-Bitach T, Encha-Razavi F, Audollent S, Soudy F, Hadchouel M, et al. Jagged1 gene expression during human embryogenesis elucidates the wide phenotypic spectrum of Alagille syndrome. Hepatology 2000;32:574-81.
80. Louis AA, Van Eyken P, Haber BA, Hicks C, Weinmaster G, Taub R, et al. Hapatic Jagged1 expression studies. Hepatology 1999;30:1269-75.
81. Morrissette JJD, Colliton RP, Spinner NB. Defective intracellular transport and processing of Jag1 missense mutations in Alagille syndrome. Hum Mol Genet 2001;10:405-13.
82. Lu F, Morrissette JJ, Spinner NB. Conditional JAG1 mutation shows the developing heart is more sensitive than developing liver to JAG1 dosage. Am J Hum Genet 2003;72:1065-70.
83. Xue Y, Gao X, Lindsell CE, Norton CR, Chang B, Hicks C, et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 1999;8:723-30.
84. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 2002;129:1075-82.
85. Gissen P, Johnson CA, Morgan NV, Stapelbroek JM, Forshew T, Cooper WN, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 2004;36:400-4.
86. Floreani A, Molaro M, Mottes M, Sangalli A, Baragiotta A, Roda A, et al. Autosomal dominant benign recurrent intrahepatic cholestasis (BRIC) unlinked to 18q21 and 2q24. Am J Med Genet 2000;95:450-3.
87. Strautnieks S, Byrne J, Knisely AS, Bull LN, Sokal E, Lacaille F, et al. There must be a third locus for low GGT PFIC. Hepatology 2001;34:240A, Abstract.
88. Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, et al. Progressive familial intrahepatic cholestasis with high gamma glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr Res 2001;50:50-5.
89. Savander M, Ropponen A, Avela K, Weerasekera N, Cormand B, Hirvioja ML, et al. Genetic evidence of heterogeneity in intrahepatic cholestasis of pregnancy. Gut 2003;52:1025-9.
90. Aagenaes O, van der Hagen CB, Refsum S. Hereditary recurrent intrahepatic cholestasis from birth. Arch Dis Child 1968;43:646-57.
91. Aagenaes O. Hereditary cholestasis with lymphoedema (Aagenaes syndrome, cholestasis-lymphoedema syndrome). New cases and follow-up from infancy to adult age. Scand J Gastroenterol 1998;33:335-45.
92. Bull LN, Roche E, Song EJ, Pedersen J, Knisely AS, van Der Hagen CB, et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000;67:994-9.
93. Fruhwirth M, Janecke AR, Muller T, Carlton VEH, Kronenberg F, Offner F, et al. Evidence for genetic heterogeneity in lymphedema-cholestasis syndrome. J Pediatr 2003;142:441-7.
94. Morris AAM, Sequeira JSS, Malone M, Slaney SF, Clayton PT. Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome). J Med Genet 1997;34:852-3.
95. Danks DM, Campbell PE, Jack I, Rogers J, Smith AL. Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child 1997;52:360-7.